The Clinical Parasitology Section is an interdisciplinary group of clinically trained LPD staff members who oversee the clinical research portfolio and provide clinical care, consultations, and training in tropical medicine and parasitology. The overriding goals of this program are
Although the Clinical Parasitology Section has protocols to see patients with any parasitic infection, the overwhelming majority of patients have neurocysticercosis, filarial infections (lymphatic filariasis, onchocerciasis, loiasis, mansonellosis), strongyloidiasis, hookworm infections, ascaraisis, giardiasis, echinococcosis, and leishmaniasis. We occasionally see patients with gnathostomiasis, African trypanosomiasis, Chagas disease, and malaria, among others.
back to top
Dr. Mahanty received his M.B.B.S. from the University of New South Wales, Sydney, Australia, and training in internal medicine at the Australian National University, Canberra, Australia. He completed his fellowship in infectious diseases at the University of Oklahoma and Case Western Reserve University and postdoctoral training in parasitology and immunology in the Laboratory of Parasitic Diseases, NIAID. He is board-certified in internal medicine and infectious diseases. He also holds a diploma/certificate in tropical medicine and travelers’ health. He held faculty appointments at McGill University (Centre for Tropical Medicine) and the Centers for Disease Control and Prevention (CDC) in Atlanta before moving to NIH in 2003. Prior to joining the Laboratory of Parasitic Diseases in 2005, he was a staff clinician in the Malaria Vaccine Development Branch (now the Laboratory of Malaria and Vaccinology), where he oversaw the immunological evaluation of malaria vaccines and was principal investigator on several clinical trials. He is the author or co-author of more than 50 publications in the field of parasitology and immunology. In addition to a research interest in parasite, viral, and vaccine immunology, he has extensive clinical experience in tropical medicine and the conduct of research protocols.
Nash TE, Garcia HH. Diagnosis and treatment of neurocysticercosis. Nat Rev Neurol. 2011 Sep 13;7(10):584-94.
Nash TE, Mahanty S, Garcia HH; Cysticercosis Group in Peru. Corticosteroid use in neurocysticercosis. Expert Rev Neurother. 2011 Aug;11(8):1175-83.
Stewart DM, Ramanathan R, Mahanty S, Fedorko DP, Janik JE, Morris JC. Disseminated Strongyloides stercoralis infection in HTLV-1-associated adult T-cell leukemia/lymphoma. Acta Haematol. 2011;126(2):63-7. Epub 2011 Apr 7.
Fink DL, Fahle GA, Fischer S, Fedorko DF, Nutman TB. Toward molecular parasitologic diagnosis: enhanced diagnostic sensitivity for filarial infections in mobile populations. J Clin Microbiol. 2011 Jan;49(1):42-7.
Ramanathan R, Talaat KR, Fedorko DP, Mahanty S, Nash TE. A species-specific approach to the use of non-antimony treatments for cutaneous leishmaniasis. Am J Trop Med Hyg. 2011 Jan;84(1):109-17.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.
Parasitic Infections of the Gastrointestinal Tract, NCT00001162
Treatment of Patients With Cysticercosis With Praziquantel or Albendazole, NCT00001205
Host Response to Infection and Treatment in Filarial Diseases, NCT00001230
Activation and Function of Eosinophilia Conditions With Blood or Tissue Eosinophilia, NCT00001406
Evaluation, Treatment, and Monitoring of Patients With A Known or Suspected Parasitic Infections, NCT00001645
Brain Tissue Swelling and Seizure Activity in Inactive Cysticercosis, NCT00001912
Diagnosis and Treatment of Leishmanial Infections, NCT00344188
Imatinib Mesylate To Treat Myeloproliferative Hypereosinophilic Syndrome, NCT00044304
A Longitudinal Study of Familial Hypereosinophilia (FE): Natural History and Markers of Disease Progression, NCT00091871
Compassionate Use of Mepolizumab Treatment in Subjects with Hypereosinophilic Syndrome, NCT00244686
A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Single-Dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa loa Infection, NCT01111305
Miltefosine To Treat Mucocutaneous Leishmaniasis, NCT01050907
Host Response to Infection and Treatment in Lymphatic Filarial Disease in India, NCT00342576
Corticosteroids To Reduce Frequency of Seizures in Neurocysticercosis Patients, NCT00290823
Changes in HIV Viral Load in Patients Undergoing Treatment for Filarial Infection, NCT00344279
Medical Implications of Coinfection With Malaria and Filariasis Parasites, NCT00471666
Effect of Albendazole Dose on Treatment of Lymphatic Filariasis, NCT00511004
Last Updated March 16, 2015
Last Reviewed September 11, 2012